Arcturus Therapeutics (ARCT) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Arcturus Therapeutics (ARCT) over the past year, gaining 15.3% versus a loss of 39.3%. Over five years, FENC leads with a +15.7% price change compared with -71.8% for ARCT. Arcturus Therapeutics is the larger company by market cap ($390.5 million vs $375.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | FENC |
|---|---|---|
| Share price | $13.74 | $10.71 |
| Market cap | $390.53M | $375.57M |
| 1-day change | +6.76% | +0.75% |
| YTD return | +109.95% | +38.05% |
| 1-year return | -39.29% | +15.29% |
| 5-year return | -71.75% | +15.67% |
| Forward P/E | — | 11.30 |
| EPS (TTM) | $-3.33 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $13.25 |
| 52-week low | $5.50 | $5.65 |
| Distance from 52-week high | -43.15% | -19.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +68.85% | +64.99% |
| Average volume | 935.23K | 193.13K |
| Shares outstanding | 28.42M | 35.07M |
| Employees | 106 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed ARCT by 54.6 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
ARCT vs FENC FAQ
Which is bigger, Arcturus Therapeutics or Fennec Pharmaceuticals?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $390.53M compared with $375.57M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, ARCT or FENC?
FENC returned +15.29% over the past 12 months, compared with -39.29% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Fennec Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arcturus Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Fennec Pharmaceuticals.